Bayer HCV/HIV Lab Tests Anticipated In 2002 Via Chiron/Ortho License
This article was originally published in The Gray Sheet
Executive Summary
Bayer immunodiagnostic lab tests for hepatitis C and HIV antibodies are expected to roll out by the end of 2002 for use on the firm's existing Advia Centaur automated immunoassay system.
You may also be interested in...
Chiron, Roche Settle HCV/HIV Patent Dispute Via $115 Mil. Licensing Pact
A licensing agreement struck between Chiron and Roche, announced Oct. 11, resolves patent litigation pending against Roche in the U.S. and overseas related to probe-based hepatitis C virus (HCV) and HIV clinical diagnostics while leaving intact complaints against Roche in Germany related to antibody-based HCV immunoassay diagnostic patents.
Bayer's $1.1 Bil. Chiron Diagnostics Buy Adds Blood Gas Analyzer Line
Acquisition of Chiron Diagnostics for $1.1 bil. provides Bayer with an entry into the blood gas analysis market, broadens clinical laboratory systems offerings and will accelerate development efforts in the field of nucleic acid diagnostics.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.